Jiangsu Hengrui Pharma A/H Listing - PHIP Updates and Updated Thoughts on A/H Premium
Jiangsu Hengrui Medicine (600276 CH) (JHP), a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing. In this note,...
511 Views
Jiangsu Hengrui Pharma A/H Listing - Recent Updates and Thoughts on A/H Premium
The company has now filed its PHIP and is said to be pre-marketing with an aim to launch the deal in the coming week. Although it would have to...
809 Views
WuXi AppTec (2359 HK): In-Line 2024 Performance; Announces Dividend and A Share Buyback Plan
1Q25 resumes double-digit growth, with revenue growing 21% YoY and net profit increasing 40% YoY. Growth was driven by Wuxi Chemistry segment. U.S....
687 Views
A/H Premiums and past A/H Listings Performance Data - Mixed Results but Size Matters
Given the slew of A/H offerings in the Hong Kong IPO pipeline, in this note, we talk about the overall A/H premiums currently.
785 Views
A-H Premium Weekly (Mar 21st): 47 Stocks at 52 Week High A-H Premium
We analyzed A-H premium changes in the past week and highlight A-H premium changes for Huadian Power, Livzon Pharma, Joinn Lab, Maanshan...
492 Views